IGC
IGC Pharma Inc
$
0.369
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
0.3738
Open
0.3656
VWAP
0.37
Vol
177.85K
Mkt Cap
33.66M
Low
0.362
Amount
65.23K
EV/EBITDA(TTM)
--
Total Shares
66.81M
EV
33.34M
EV/OCF(TTM)
--
P/S(TTM)
21.81
IGC Pharma, Inc. is a clinical-stage company, which is engaged in developing treatments for Alzheimer’s disease. The Company’s flagship drug, IGC-AD1, is an investigational drug tackles agitation, a major burden for patients and caregivers by addressing neuroinflammation. The Company operates through two segments: Life Sciences Segment and Infrastructure Segment. Its TGR-63 has demonstrated its potential to disrupt the progression of Alzheimer’s by targeting Aβ plaques, a key disease hallmark. The Company’s IGC-1C represents a potential breakthrough by targeting tau protein and neurofibrillary tangles, aiming to modify the disease course. Its IGC-M3 focuses on early intervention by inhibiting Aβ plaque formation, potentially slowing cognitive decline. Its LMP is designed to target multiple hallmarks of Alzheimer’s disease, including Aβ plaques and neurofibrillary tangles for a comprehensive therapeutic effect. It seeks to leverage artificial intelligence (AI) for Alzheimer's research.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q4
FY2026Q3
FY2026Q2
373.50K
+13.18%
-0.020
+100%
316.50K
+23.15%
-0.020
-0%
383.00K
-7.04%
-0.020
-0%
Estimates Revision
The market is revising Downward the revenue expectations for IGC Pharma, Inc. (IGC) for FY2026, with the revenue forecasts being adjusted by -6.57% over the past three months. During the same period, the stock price has changed by 3.80%.
Revenue Estimates for FY2026
Revise Downward
-6.57%
In Past 3 Month
EPS Estimates for FY2026
No Change
0.00%
In Past 3 Month
Stock Price
Go Up
+3.80%
In Past 3 Month
1 Analyst Rating
Wall Street analysts forecast IGC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IGC is 4.50 USD with a low forecast of 4.50 USD and a high forecast of 4.50 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.369
Low
4.50
Averages
4.50
High
4.50
Current: 0.369
Low
4.50
Averages
4.50
High
4.50
Alliance Global Partners
James Molloy
Strong Buy
Reiterates
$3.5
2025-03-06
Reason
Alliance Global Partners
James Molloy
Price Target
$3.5
2025-03-06
Reiterates
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$4 → $4.25
2025-02-24
Reason
Ascendiant Capital
Edward Woo
Price Target
$4 → $4.25
2025-02-24
Maintains
Strong Buy
Reason
Ascendiant Capital
Edward Woo
Strong Buy
Maintains
$3.75 → $4
2024-12-05
Reason
Ascendiant Capital
Edward Woo
Price Target
$3.75 → $4
2024-12-05
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for IGC Pharma Inc (IGC.A) is -4.58, compared to its 5-year average forward P/E of -1.50. For a more detailed relative valuation and DCF analysis to assess IGC Pharma Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-1.50
Current PE
-4.58
Overvalued PE
0.14
Undervalued PE
-3.14
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10.25
Current PS
0.37
Overvalued PS
21.42
Undervalued PS
-0.91
Financials
Annual
Quarterly
FY2026Q1
YoY :
+20.59%
328.00K
Total Revenue
FY2026Q1
YoY :
-19.75%
-1.90M
Operating Profit
FY2026Q1
YoY :
-32.76%
-1.60M
Net Income after Tax
FY2026Q1
YoY :
-33.33%
-0.02
EPS - Diluted
FY2026Q1
YoY :
-18.80%
-1.53M
Free Cash Flow
FY2026Q1
YoY :
-21.66%
46.95
Gross Profit Margin - %
FY2026Q1
-370.99
FCF Margin - %
FY2026Q1
YoY :
-44.24%
-487.50
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IGC News & Events
Events Timeline
2025-11-13 (ET)
2025-11-13
09:16:48
New
IGC Pharma Receives U.S. Patent for IGC-AD1
2025-11-03 (ET)
2025-11-03
08:57:08
IGC Pharma Enhances AI-Driven In-Silico Drug Discovery Platform
2025-10-14 (ET)
2025-10-14
09:07:12
IGC Pharma extends Phase 2 CALMA trial to include the University of South Florida
Sign Up For More Events
Sign Up For More Events
News
4.0
10-24NASDAQ.COMEssential Information on IGC Pharma, Inc. (IGC) Following Rating Upgrade to Strong Buy
4.0
10-24NASDAQ.COMTop Strong Buy Stocks for October 24: IGC, ASM, and Others
8.5
07-10BenzingaWhy WK Kellogg Shares Are Trading Higher By Over 50%; Here Are 20 Stocks Moving Premarket
Sign Up For More News
People Also Watch
PZG
Paramount Gold Nevada Corp
1.125
USD
-3.02%
NXGL
Nexgel Inc
2.090
USD
+3.47%
XCUR
Exicure Inc
3.640
USD
+1.11%
ORKT
Orangekloud Technology Inc
1.197
USD
-1.07%
NAII
Natural Alternatives International Inc
3.330
USD
+18.51%
CPSH
CPS Technologies Corp
3.510
USD
+6.36%
CVV
CVD Equipment Corp
3.185
USD
+0.47%
NISN
Nisun International Enterprise Development Group Co Ltd
3.700
USD
0.00%
FAQ
What is IGC Pharma Inc (IGC) stock price today?
The current price of IGC is 0.3688 USD — it has increased 0.82 % in the last trading day.
What is IGC Pharma Inc (IGC)'s business?
What is the price predicton of IGC Stock?
What is IGC Pharma Inc (IGC)'s revenue for the last quarter?
What is IGC Pharma Inc (IGC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for IGC Pharma Inc (IGC)'s fundamentals?
How many employees does IGC Pharma Inc (IGC). have?